GBI Research, a leading business intelligence provider, has released its latest research “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development”, which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.

1. Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology
Pipeline Leads with Most Promising Molecules in Late Stage Development
GBI Research, a leading business intelligence provider, has released its latest research
“Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology
Pipeline Leads with Most Promising Molecules in Late Stage Development”, which provides
insights into the unmet needs targeted by late stage pipeline molecules across major
therapy areas. The report examines the safety, efficacy parameters of molecules in
development. The report includes insights into the R&D pipeline various therapy areas and
identifies potential blockbusters.
Buy Now: Late Stage Pipeline Molecules in Major Indications Market
Browse All: Latest Market Research Reports
In-depth analysis of the report is based on propriety databases, primary and secondary
research and in-house analysis by GBI Research’s team of experts.
Scope
Profiles of promising late stage pipeline molecules across various therapy areas
Analysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at major
therapy areas
Comparison of late stage drugs based on safety, efficacy, mechanism of action, unmet need
targeted and stage of disease targeted
Reasons to buy
Build effective strategies to launch their pipeline products by identifying geographies with
high potential for growth.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill
their portfolio gaps.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-
class molecules which are safer and more efficacious.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Introduction
2.1 GBI Research Report Guidance
3 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Oncology
3.1 Comparative Analysis of Late Stage Pipeline Molecules in NSCLC

2. 3.1.1 Overview
3.1.2 Opportunity and Unmet Need
3.1.3 Strategic Pipeline Assessment
3.1.4 Comparative Analysis of Late Stage Pipeline Molecules Based on Major Characteristics
3.1.5 Promising Drugs under Clinical Development
3.1.6 Other Promising Drugs under Clinical Development
3.2 Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer
3.2.1 Overview
3.2.2 Opportunity and Unmet Need
3.2.3 Strategic Pipeline Assessment
3.2.4 Trends in Colorectal Cancer Pipeline
3.2.5 Comparative Analysis Based on Major Characteristics
3.2.6 Promising Drugs Under Clinical Development
3.3 Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer
3.3.1 Overview
3.3.2 Opportunity and Unmet Need
3.3.3 Strategic Pipeline Assessment
3.3.4 Comparative Analysis Based on Major Characteristics
3.3.5 Promising Drugs under Clinical Development
3.4 Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer
3.4.1 Overview
3.4.2 Opportunity and Unmet Need
3.4.3 Strategic Pipeline Assessment
3.4.4 Trends in Prostate Cancer Pipeline
3.4.5 Comparative Analysis Based on Major Characteristics
3.4.6 Promising Drugs under Clinical Development
4 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Metabolic Disorders
4.1 Comparative Analysis of Late Stage Pipeline Molecules in Type II Diabetes
4.1.1 Overview
4.1.2 Opportunity and Unmet Need
4.1.3 Strategic Pipeline Assessment
4.1.4 Comparative Analysis Based on Major Characteristics
4.1.5 Promising Drugs under Clinical Development
5 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Respiratory Diseases
5.1 Comparative Analysis of Late Stage Pipeline Molecules in COPD
5.1.1 Overview
5.1.2 Opportunity and Unmet Need
5.1.3 Strategic Pipeline Assessment
5.1.4 Comparative Analysis Based on Major Characteristics
5.1.5 Promising Drugs under Clinical Development
6 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Musculoskeletal
6.1 Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis
6.1.1 Overview
6.1.2 Opportunity and Unmet Need

3. 6.1.3 Strategic Pipeline Assessment
6.1.4 Comparative Analysis Based on Major Characteristics
6.1.5 Promising Drugs under Clinical Development
7 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Central Nervous System
7.1 Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy
7.1.1 Overview
7.1.2 Opportunity and Unmet Need
7.1.3 Strategic Pipeline Assessment
7.1.4 Comparative Analysis Based on Major Characteristics
7.1.5 Promising Drugs under Clinical Development
7.2 Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis
7.2.1 Overview
7.2.2 Opportunity and Unmet Need
7.2.3 Strategic Pipeline Assessment
7.2.4 Comparative Analysis Based on Major Characteristics
7.2.5 Promising Drugs under Clinical Development
7.3 Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive Disorder
7.3.1 Overview
7.3.2 Opportunity and Unmet Need
7.3.3 Strategic Pipeline Assessment
7.3.4 Comparative Analysis Based on Major Characteristics
7.3.5 Promising Drugs under Clinical Development
8 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Immunology
8.1 Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease
8.1.1 Overview
8.1.2 Opportunity and Unmet Need
8.1.3 Strategic Pipeline Assessment
8.1.4 Comparative Analysis Based on Major Characteristics
8.1.5 Promising Drugs under Clinical Development
9 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Cardiovascular
9.1 Comparative Analysis of Late Stage Pipeline Molecules in Hypertension
9.1.1 Overview
9.1.2 Opportunity and Unmet Need
9.1.3 Strategic Pipeline Assessment
9.1.4 Comparative Analysis Based on Major Characteristics
9.1.5 Promising Drugs under Clinical Development
10 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Infectious Disease
10.1 Comparative Analysis of Late Stage Pipeline Molecules in HIV/ AIDS
10.1.1 Overview
10.1.2 Opportunity and Unmet Need
10.1.3 Strategic Pipeline Assessment

4. 10.1.4 Comparative Analysis Based on Major Characteristics
10.1.5 Promising Drugs under Clinical Development
11 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Gastrointestinal Diseases
11.1 Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis
11.1.1 Overview
11.1.2 Opportunity and Unmet Need
11.1.3 Strategic Pipeline Assessment
11.1.4 Comparative Analysis Based on Major Characteristics
11.1.5 Promising Drugs under Clinical Development
12 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Conclusion
12.1 Oncology Pipeline Holds Most Prominence for Market Players
12.2 Colorectal Cancer Most Noteworthy Indications With Respect To Phase III Activity
12.3 An Average Of 50% Unmet Need Common in Oncology Therapeutics Followed By RA
12.4 Kinase Inhibitors – Most Important First-In-class Drug
12.5 Receptor Tyrosine Kinase and Vaccines Are Major Promising Class Based On Sales
Forecast for Oncology
13 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Appendix
13.1 Marketed Definitions
13.2 Abbreviations
13.3 Research Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research
13.3.4 Expert Panel Validation
13.4 Contact Us
13.5 Disclaimer
13.6 Sources
List of Tables
Table 1: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Based on Major
Characteristics
Table 2: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Other Promising
Candidates in Late Stage Pipeline, 2011
Table 3: Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer, Based
on Major Characteristics
Table 4: Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer, Based on
Major Characteristics
Table 5: Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer, Based on
Major Characteristics
Table 6: Comparative Analysis of Late Stage Pipeline Molecules in Type 2 Diabetes, Based
on Major Characteristics
Table 7: Comparative Analysis of Late Stage Pipeline Molecules in COPD, Based on Major
Characteristics

5. Table 8: Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis,
Based on Major Characteristics
Table 9: Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy, Based on Major
Characteristics
Table 10: Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis, Based
on Major Characteristics
Table 11: Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive
Disorder, Based on Major Characteristics
Table 12: Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease, Based
on Major Characteristics
Table 13: Comparative Analysis of Late Stage Pipeline Molecules in Hypertension, Based on
Major Characteristics
Table 14: Comparative Analysis of Late Stage Pipeline Molecules in HIV/AIDS, Based on
Major Characteristics
Table 15: Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis, Based
on Major Characteristics
List of Figures
Figure 1: NSCLC Pipeline, Global, Mechanism of Action, 2010
Figure 2: NSCLC Pipeline, Global, Technology Analytics Framework, 2010
Figure 3: Colorectal Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 4: Colorectal Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 5: Breast Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 6: Breast Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 7: Prostate Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 8: Prostate Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 9: Type 2 Diabetes Pipeline, Global, Mechanism of Action, 2010
Figure 10: Type 2 Diabetes Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 11: COPD Pipeline, Global, Mechanism of Action, 2010
Figure 12: COPD Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 13: Rheumatoid Arthritis Pipeline, Global, Mechanism of Action, 2010
Figure 14: Rheumatoid Arthritis Pipeline, Global, Technology Trends Analytic Framework,
2010
Figure 15: Epilepsy Pipeline, Global, Mechanism of Action, 2010
Figure 16: Epilepsy Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 17: Multiple Sclerosis Pipeline, Global, Mechanism of Action, 2010
Figure 18: Multiple Sclerosis Pipeline, Global, Technology Trends Analytic Framework, 2009
Figure 19: Major Depressive Disorder Pipeline, Global, Mechanism of Action, 2010
Figure 20: Major Depressive Disorder Pipeline, Technology Trends Analytic Framework, 2011
Figure 21: Crohn’s Disease Pipeline, Global, Mechanism of Action, 2010
Figure 22: Crohn’s Disease Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 23: Anti-hypertension Pipeline, Global, Mechanism of Action, 2010
Figure 24: Anti Hypertension Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 25: HIV/AIDS Pipeline, Global, Mechanism of Action, 2010
Figure 26: HIV/ AIDS Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 27: Ulcerative Colitis Pipeline, Global, Mechanism of Action, 2010
Figure 28: Ulcerative Colitis Pipeline, Global, Technology Trends Analytic Framework, 2009
Figure 29: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, by
Therapy Area, 2011

6. Figure 30: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, by
Phase, 2011
Figure 31: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications,
Unmet Needs in % and $m, 2009
Figure 32: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications,
Technology Trends, 2011
Figure 33: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, Sales
Forecast of Some Key Late Stage Pipeline Drugs in Oncology, ($m), 2017
Latest Market Research Reports:
Middle East and Africa (MEA) System Integration (SI) Services Market Analysis and Forecast
(2011-2016)
Food Shopper Insights: Grocery Shopping Trends in the U.S.
Hotel Foodservice Trends in the U.S.
Natural and Organic Foods and Beverages in the U.S., 3rd Edition
Trends in U.S. Foodservice Contracting
Underbanked and Unbanked Consumers in the U.S.: Successfully Targeting Consumers of
Alternative Financial Services
Thin Film Solar PV Manufacturing Equipment Worldwide
Drugs of Abuse Testing Markets
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com